Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Registry Trial of the Bioheart Rapamycin Drug-Eluting Bioresorbable Coronary Stent System in Patients With Coronary Artery Disease: BIOHEART Ⅲ

NCT04179045 is registered in ClinicalTrials.gov with Shanghai Bio-heart Biological Technology Co., Ltd. as lead sponsor.

NCT NCT04179045
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04179045 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Registry Trial of the Bioheart Rapamycin Drug-Eluting Bioresorbable Coronary Stent System in Patients With Coronary Artery Disease: BIOHEART Ⅲ
Lead sponsor
Shanghai Bio-heart Biological Technology Co., Ltd.
Phase
Not applicable
Overall status
Unknown status
Start date
March 1, 2021
Completion date
July 31, 2026
Enrollment
785 (estimated)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

coronary artery disease